MAPK13

Across TCGA pan-cancer cohorts, MAPK13 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MAPK13 data layer compared with 22 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher MAPK13 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MAPK13 expression acts as an unfavorable survival marker.

STAD, PAAD, and PCPG are the cancer types where MAPK13 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.199	0.730	.002	24	view →
PAAD	OS	Median	All	0.132	0.590	<.001	12	view →
PCPG	DFS	Median	All	0.229	0.822	.024	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MAPK13–STAD (OS)

Open the STAD breakdown →